Several interventions can slow macular degeneration, and a few newer treatments can even reduce the damage it causes. What helps most depends on which type you have (dry or wet) and how far it has progressed. The combination of targeted supplements, lifestyle changes, medical treatments, and daily monitoring gives you the strongest defense against vision loss.
AREDS2 Supplements for Intermediate AMD
The most well-studied intervention for slowing age-related macular degeneration is a specific vitamin and mineral formula tested in two large clinical trials funded by the National Eye Institute. Taking the AREDS2 supplement reduces the risk of progressing from intermediate to advanced AMD by about 25 percent. That benefit is meaningful, but it applies specifically to people who already have intermediate AMD or advanced AMD in one eye. If you have only early-stage changes, the formula hasn’t been shown to help.
The AREDS2 formula contains 500 mg of vitamin C, 400 IU of vitamin E, 80 mg of zinc, 2 mg of copper, 10 mg of lutein, and 2 mg of zeaxanthin. Many brands sell supplements labeled “eye health” that don’t match these exact amounts, so check the label carefully. The original AREDS formula included beta-carotene, which was dropped in the AREDS2 version because it increased lung cancer risk in smokers. Lutein and zeaxanthin replaced it and provided a small additional benefit. Adding omega-3 fatty acids to the formula did not reduce risk further.
Diet and the Nutrients That Matter Most
Lutein and zeaxanthin are pigments that accumulate in the macula and act as a natural filter against damaging light. Your body can’t make them, so they come entirely from food. The richest sources are dark leafy greens: kale and spinach top the list, with kale containing up to 115 micrograms of lutein per gram of fresh weight and spinach close behind at 59 to 79 micrograms. Parsley and basil are also exceptionally high. Beyond greens, peas, broccoli, leeks, and egg yolks all contribute meaningful amounts.
A diet built around these foods supports macular health whether or not you take supplements. Colorful vegetables like red and green peppers add zeaxanthin specifically. There’s no precise daily intake threshold proven to prevent AMD, but consistently eating several servings of leafy greens per week aligns with the dietary patterns seen in people who develop AMD less often.
Smoking Is the Largest Modifiable Risk Factor
Current smokers face a two- to four-fold increase in AMD risk compared to people who have never smoked. That makes smoking the single biggest controllable contributor to the disease. Quitting helps, but the risk stays elevated for a long time. The Rotterdam Study found that former smokers still carry increased risk of the wet (neovascular) form for up to 20 years after quitting. Only after roughly two decades does the risk return to the level of someone who never smoked.
That 20-year timeline isn’t a reason to delay quitting. It’s a reason to quit as early as possible. Every year of continued smoking adds cumulative damage to the blood vessels and pigment cells in the retina that you can’t reverse.
Exercise as a Protective Factor
A meta-analysis of seven population-based studies covering more than 14,600 adults found that people with low or no physical activity had a 19 percent higher risk of developing early AMD compared to those with high activity levels. The effect was consistent across age groups, suggesting that exercise protects the retina through mechanisms that aren’t simply explained by being younger or healthier overall. Improved blood flow, reduced inflammation, and better cardiovascular health all likely play a role. Regular aerobic activity, the kind that raises your heart rate for 30 minutes or more, is the type most studied.
Treatments for Wet AMD
Wet AMD occurs when abnormal blood vessels grow beneath the retina and leak fluid, causing rapid vision loss. The standard treatment is a series of injections directly into the eye that block a protein called VEGF, which drives that abnormal vessel growth. Several of these drugs are available, including options approved as recently as 2022.
Treatment typically starts with at least three monthly injections. After that initial phase, your eye doctor checks for signs of active disease (fluid, bleeding) using imaging scans. If things look stable, the interval between injections gradually extends, potentially stretching to every 16 weeks or longer with newer, longer-acting drugs. If the disease flares, the interval shortens again. Most people receive around seven or eight injections in the first year.
Starting treatment quickly matters. Guidelines recommend beginning injections as soon as wet AMD is diagnosed. Delays allow more irreversible damage to the macula. The injections don’t restore lost vision in most cases, but they can stabilize what remains and sometimes improve it.
Newer Treatments for Advanced Dry AMD
Advanced dry AMD, called geographic atrophy, had no approved treatment until 2023. Two drugs that target the complement system (part of the immune response involved in destroying retinal cells) received FDA approval that year. Both are given as eye injections, either monthly or every other month.
These treatments don’t reverse geographic atrophy, but they slow its expansion. In clinical trials, one of the drugs reduced the rate of lesion growth by 14 to 19 percent over two years compared to no treatment, with the effect roughly doubling between the first and second year. That may sound modest, but for a condition that previously had no treatment at all, slowing progression preserves functional vision longer. The treatments are most relevant for people whose geographic atrophy hasn’t yet reached the very center of the macula, where the sharpest vision lives.
Monitoring Your Vision at Home
An Amsler grid is a simple printed chart with a grid of straight lines and a central dot. Using it daily can catch changes early, especially the sudden shift from dry to wet AMD that requires urgent treatment. The American Academy of Ophthalmology recommends testing once a day, every day.
To use it: wear your normal reading glasses, hold the grid 12 to 15 inches from your face in good light, cover one eye, and focus on the center dot. While staring at that dot, notice whether any lines in your peripheral vision look wavy, blurry, dark, or blank. Repeat with the other eye. If you notice new waviness, dark spots, or blank areas that weren’t there before, contact your eye doctor immediately. That kind of change can signal new fluid or bleeding under the retina, and getting treatment within days rather than weeks makes a real difference in outcomes.
Low Vision Aids and Assistive Devices
When macular degeneration has already caused significant central vision loss, a range of devices can help you maintain independence. These fall into a few categories. Optical magnifiers, including handheld, stand, and dome styles, enlarge printed text for reading. Half-eye spectacle magnifiers are hands-free and allow both eyes to work together, making reading and writing more comfortable over longer periods. For distance tasks like watching television or recognizing faces, spectacle-mounted telescopes can magnify objects across a room.
Electronic portable video magnifiers offer the widest range of magnification (up to 25 times) and let you switch to high-contrast or reverse-contrast modes, which many people with AMD find dramatically easier to read. On phones and computers, built-in accessibility settings for larger text, bold fonts, and high contrast can make a meaningful difference without any special equipment. Additional lighting, particularly adjustable task lighting for reading, is one of the simplest and most effective changes you can make at home.
For people with end-stage AMD who meet specific criteria, an implantable miniature telescope is a surgical option. It’s designed for those 65 and older with stable, severe central vision loss, who still have a cataract in the eye (no prior cataract surgery), and who demonstrate improved vision with an external telescope during a trial period. The device won’t restore pre-AMD vision, but it can improve independence enough to reduce reliance on caregivers.